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Introduction. The study aimed to report the efficiency of radical radiotherapy and chemoradiotherapy in patients with 
non-small cell lung cancer (NSCLC) treated in the Nu-Med Radiotherapy Center in Elbląg.
Material and methods. Ninety-two patients diagnosed with NSCLC treated between 2013 and 2016 were included in 
the analysis. Overall survival (OS) was estimated by the Kaplan-Meier method.
Results. The 2-year OS for all patients was 36% (median 1.5 years). Two prognostic factors had a significant impact: tre-
atment method and performance status (PS). Patients who underwent concurrent radiochemotherapy and were treated 
sequentially had a better 2-year OS in comparison with those treated with radiotherapy alone (respectively 46% and 37% 
vs. 25%, p ≤ 0.05). Patients with PS 0–1 had better OS (median 1.6 years) compared with PS 2 (median 0.7 years, p = 0.04). 
Other prognostic factors analysed had no impact on OS in our study.
Conclusions. The treatment results of our patients are comparable to those in published trials and meta-analyses. 
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Introduction
In 2013, of more than 12.7 million malignancies diagnosed 
worldwide, about 13% (1.6 million) were lung malignancies. 
In Poland, lung cancer is the most common type of cancer in 
men, and among women it ranks third. It’s also the prime cause 
of death from malignancy for both sexes [1]. Cigarette smoking 
is the leading cause of lung cancer development. Smoking 
increases its risk 20–30 fold [2, 3]. The treatment method of 
patients diagnosed with lung cancer depends mainly on the 
clinical stage of the disease and patient comorbidities. One 
of the reasons for the poor prognosis is late diagnosis, and 
therefore most patients are disqualified from radical surgery 
[4]. According to EUROCARE 5 (EUROpean CAncer REgistry 
based study on the survival and care of cancer patients), the 
5-year relative survival of lung cancer patients diagnosed be-
tween 2000 and 2007 was 14.3% for Poland, and the European 
average was 12.6% [5]. The most frequent histology of lung 
cancer is non-small cell lung cancer (NSCLC) [6]. The 5-year 
overall survival of patients diagnosed with NSCLC depending 
on clinical stage ranges 4–66% [7]. For patients with early-stage 
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NSCLC surgery remains the primary treatment; for locally ad-
vanced non-small cell lung cancer chemoradiotherapy is the 
treatment of choice. However, the effectiveness of the latter 
leaves much to be desired. We have particularly high hopes for 
the addition of immunotherapy to chemoradiotherapy, which 
has significantly improved survival in inoperable patients [8].
However, there are some limitations to the data supporting 
treatment strategies in specific patient subsets and studies 
have included heterogeneous patient populations. The de-
finition of clinical stage III has changed over time, and early 
reviews have often been inadequately powered to detect 
small differences in survival outcome, have not been rando-
mised or have had limited time of follow-up. Development 
in therapy: the use of more active chemotherapy agents and 
refinements in radiation and surgical techniques also limit the 
interpretation of earlier clinical trials [9]. The aim of this study 
was to analyse and report the outcome of the treatment of 
non-small cell lung cancer patients with radical radiotherapy 
and chemoradiotherapy in our department.
Material and methods 
A list of patients was generated from the institutional data-
base, Mosaiq and Clininet systems. The medical records of all 
patients were available for this study. The research was con-
ducted on a group of 109 patients with primary, unresectable, 
non-metastatic cancers, with a histopathological diagnosis of 
non-small cell lung cancer, who underwent curative radio- and 
radiochemotherapy between 2013 and 2016 in the Nu-Med 
Radiotherapy Center in Elbląg. Seventeen patients were exclu-
ded from the analysis. The reason for exclusion was resection in 
11 patients (10%), including nine patients treated with posto-
perative radiation and two patients treated with preoperative 
radiochemotherapy. Six patients (6%) who underwent therapy 
because of recurrence were also excluded from the analysis. All 
patients were staged with computed tomography of the chest 
and abdominal ultrasound, 57 (62%) had PET examinations, 
87 (95%) had a spirometric evaluation.
The stage was determined by the UICC TNM classification 
of Malignant Tumours – 7th edition. A total dose of 66 Gy with 
fraction dose 2 Gy was administrated in 55 patients, 66 Gy 
(fraction dose 2.2 Gy) in 8 patients, 60 Gy (fraction dose 2 Gy) 
in 27 cases and 50 Gy in 2 patients. Dose 60 Gy was prescribed 
for concomitant treatment, 66 Gy for the sequential scheme 
or for radiotherapy alone. The dose of 50 Gy was prescribed 
for tumours infiltrating vertebral bodies close to the spine. 
The CTV included lung tumour and pathological lymph nodes 
with 8 mm margins. In post-chemotherapy cases, the CTV 
consisted of residual lung tumour and lymph nodes with an 
8 mm margin and initially involved mediastinal node groups. In 
both scenarios, the PTV was created by adding 7 mm margins 
radially and 10 mm in the craniocaudal direction.
Treatment plans were prepared using Prowess or Eclipse 
software. Radiotherapy was delivered with Artiste (Siemens) 
Liniacs, using photons X 6 MV, with IMRT in 79 patients (86%) 
and 3D technique in 13 (14%). The method was chosen by 
attending a radiation oncologist, after DVH comparison. 
Patients treated with chemoradiotherapy received diffe-
rent chemotherapy regimens: carboplatin-vinorelbine (KN) 
(6 patients), cisplatin-vinorelbine (PN) (47 patients), carbopla-
tin-etoposide (KE) (1 patient), cisplatin-etoposide (PE) (6 pa-
tients), cisplatin (1patient), cisplatin-pemetrexed (1 patient), 
KN+PN (1 patient), KN+PXL/CDDP (1 patient). The induction 
chemotherapy regimen was chosen and administered by 
medical oncologists from other hospitals. 
The efficacy of radiotherapy and chemoradiotherapy was 
estimated by survival analysis from the date of the beginning 
of the treatment to the last follow-up visit/death. Variables that 
can impact patient survival (sex, age, BMI, place of residence, 
the distance between the place of residence and Nu-Med 
Center, baseline WHO PS, clinical stage, lymph node status, 
tumour localisation, type of histopathology, type of treatment) 
were analysed.
The proportion between subgroups: radiotherapy alone 
vs. sequential radiochemotherapy vs. concurrent radiochemo-
therapy in different factors were compared using the chi2 test. 
Overall survival (OS) was estimated by the Kaplan-Meier me-
thod and differences in survival were compared by the log-rank 
test. Uni- and multivariable analysis was estimated through 
the Cox regression model. Univariate variables with p < 0.25 
were included in the multivariable analysis. A p-value <0.05 
was considered to be significant. The analysis was performed 
using TIBCO Software Inc. (2017) and Statistica (a data analysis 
software system), version 13. http://statistica.io.
Results
Ninety-two patients were included in the analysis. The majority 
of patients were men (72; 78%) and lived in cities ≤100 tho-
usand (44; 48%) and villages (31; 34%). The median age was 
64 years. Half of the patients (47; 51%) were of PS (performance 
status) grade 0 according to the WHO/ECOG scale during the 
first visit. Most patients were treated in clinical stage IIIA (53; 
58%) and IIIB (31; 34%), with T3–4 (70%), with N2–3 (80%), with 
squamous cell carcinoma (68; 74%) and adenocarcinoma (19; 
21%), tumour localisation on right side (59; 64%). Over half 
(57; 62%) had a PET examination before treatment. 28 patients 
(30%) underwent radiotherapy only, 38 patients (41.5%) had 
sequential radiochemotherapy and 26 patients (28.5%) had 
concurrent radiochemotherapy. Most patients (58; 63%) were 
referred from Szpital Specjalistyczny in Prabuty (the regional 
pulmonological center) for treatment to the Nu-Med Center 
and the 34 remaining patients (37%) where diagnosed in 
hospitals in Elbląg (tab. I).
More patients who received radiotherapy alone were >64 
years compared with patients who underwent sequential or 
concurrent radiochemotherapy, respectively 89% vs. 32% vs. 
23% (p < 0.001). There was a significant difference in perfor-
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Table I. Characteristics of patients








    N % N % N % N % p
    92 100 28 30 38 41.5 26 28.5
Age (start of radiotherapy) range: 46–82 years; median: 64 years 
  ≤64 49 53 3 11 26 68 20 77
<0.001
  >64 43 47 25 89 12 32 6 23
Sex                    
  women 20 22 5 18 9 24 6 23
0.84
  men 72 78 23 82 29 76 20 77
BMI range: 15.8–46.1; median 26
  ≤26 42 46 15 53.5 18 47 9 34.5
0.46  >26 42 46 12 43 16 42 14 54
  no data 8 9 1 3.5 4 11 3 11.5
Place of residence                    
  village 31 34 9 32 13 34 9 34.5
0.08  cities ≤100 thous 44 48 14 50 22 58 8 31
  cities >100 thous 17 18 5 18 3 8 9 34.5
Distance from place of 
residence to Nu-Med. Center
range: 0–616 km; median 67 km 
  ≤67 47 51 13 46 17 45 17 65
0.22
  >67 45 49 15 54 21 55 9 35
Performance status according WHO/ECOG during first visit 
  0 47 51 10 36 17 45 20 77
0.02  1 37 40 14 50 17 45 6 23
  2 8 9 4 14 4 10 0 0
Clinical stage                    
  IB 3 3 3 11 0 0 0 0
0.02
  IIA 2 2 2 7 0 0 0 0
  IIB 3 3 2 7 1 3 0 0
  IIIA 53 58 16 57 19 50 18 69
  IIIB 31 34 5 18 18 47 8 31
Lymph nodes status                    
  N+ 79 86 20 71 35 92 24 92
0.03
  N– 13 14 8 29 3 8 2 8
Tumor localization                    
  right 59 64 17 61 26 68 16 61
0.97*
  left 29 32 9 32 12 32 8 31
  mediastinum 3 3 2 7 0 0 1 4  
  right and left 1 1 0 0 0 0 1 4  
Type of histopathology                    
  planoepitheliale 68 74 19 68 30 79 19 73
0.74^
  adenocarcinoma 19 21 7 25 7 18 5 19
  undetermined 5 5 2 7 1 3 2 8  
PET                    
  yes 57 62 21 75 14 37 22 85
<0.001
  no 35 38 7 25 24 63 4 15
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mance status (PS) according to the WHO/ECOG classification 
during the first visit between patients treated with concurrent 
radiochemotherapy (no one with PS 2) vs. sequential radioche-
motherapy (10% of patients with PS 2) or radiotherapy alone 
(14% of patients with PS 2) (p = 0.02). Patients who underwent 
a different type of treatment significantly differed in terms of 
characteristics: clinical stage, lymph node status, PET exami-
nation and the time of treatment from radiochemotherapy to 
the end of radiotherapy (tab. I).
The 2-year overall survival for all patients was 36%. The 
median OS (mOS) was 1.5 years (95% confidence interval (CI): 
0.7–2.8 years; (fig. 1). 31 deaths (34%) were observed during 
the first year, including 13 patients treated with radiothera-
py alone, 9 with sequential radiochemotherapy and 9 with 
concurrent radiochemotherapy. Patients who underwent 
radiotherapy alone had a statistically significant worse 2-year 
OS (25%; mOS 1.1 years [95% CI: 0.5–1.9 years]) in compari-
son with patients treated with concurrent (46%; mOS 1.1 
years [95% CI: 0.5–not reached]; p = 0.05) and sequential 
radiochemotherapy (37%; mOS 1.7 years [95% CI: 1.0–2.6 
years]; p = 0.03). There was no significant difference obse-
rved between concurrent and sequential radiochemotherapy 
(p = 0.54) (fig. 2, tab. II). Patients with PS 0–1 during the first 
consultation had a significantly better mOS – 1.6 years (95% 
CI: 0.7–3.5 years) than patients with PS 2 – mOS 0.7 years (95% 
CI: 0.4–1.1 years; p = 0.04) (fig. 3, tab. II). Total treatment time, 
age, sex, BMI, place of residence, the distance from the place 
of residence to the Nu-Med Center, lymph node metastasis, 
tumour localisation, type of histopathology, clinical stage, 
PET examination had no impact on OS (tab. II).








    N % N % N % N % p
Time of treatment from 
radiochemotherapy to end 
of radiotherapy 
range: 15–208 days; median 47.5 days
  ≤47.5 46 50 26 93 0 0 20 77
<0.001
  >47.5 46 50 2 7 38 100 6 23
*p-value – comparison of the percentages between subgroups: right and left tumor localization 
^p-value – comparison of the percentages between subgroups: planoepitheliale and adenocarcinoma type of histopathology
Table II. Overall survival of patients
    2-year OS (%) Median OS [years] (95% CI) Log-Rank test p
All   36 1.5 (0.7–2.8)
Age (at start of radiotherapy)
  ≤64 years 39 1.6 (0.7–4.2)
0.17
  >64 years 33 1.5 (0.6–2.2)
Sex          
  women 50 1.6 (0.7–2.9)
0.42
  men 32 1.5 (0.6–2.2)
BMI          
  ≤26 36 1.5 (0.5–2.3)
0.76
  >26 36 1.6 (0.9–3.2)
Place of residence          
  village 39 1.5 (0.7–not reached)
0.72   cities ≤100 thous 32 1.5 (0.7–2.3)
  cities >100 thous 41 1.6 (0.2–3.7)
The distance from place of residence to Nu-Med Center 
  ≤67 km 30 1.5 (0.5–2.2)
0.29
  >67 km 42 1.6 (0.9–3.1)
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    2-year OS (%) Median OS [years] (95% CI) Log-Rank test p
Performance status according to WHO/ECOG scale during first visit
  0–1 39 1.6 (0.7–3.5)
0.04
  2                – 0.7 (0.4–1.1)
Clinical stage          
  IB 33 1.9 (0.4–4.1)
0.63 
  IIA 50 0.2 (0.2–2.3)
  IIB                – 0.6 (0.5–1.7)
  IIIA–B 37 1.5 (0.7–3.1)
Lymph node status          
  N+ 37 1.5 (0.7–2.6)
0.78
  N– 31 1.7 (0.5–3.1)
Tumor localization          
  right 38 1.6 (0.7–2.6)
0.51* 
  left 38 1.6 (0.7–not reached)
Type of histopathology
  planoepitheliale 32 1.5 (0.6–2.2)
0.29^ 
  adenocarcinoma 47 1.6 (1.0–4.2)
PET          
  yes 40 1.5 (0.6–3.6)
0.52
  no 28 1.5 (0.7–2.1)
Time of treatment from radiochemotherapy to end of radiotherapy 
  ≤47.5 days 37 1.2 (0.5–2.6)
0.55
  >47.5 days 35 1.6 (1.0–2.6)
Type of treatment          
  alone radiotherapy 25 1.1 (0.5–1.9)
0.07   sequential radiochemotherapy 37 1.7 (1.0–2.6)
  concurrent radiochemotherapy 46 1.1 (0.5–not reached)
* patients with mediastinum tumor localization were excluded from the analysis
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Figure 1. Overall survival for all patients Figure 2. Overall survival by type of treatment
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In univariate analysis, only three factors met the inclusion 
criteria to a multivariate regression model (p < 0.25). In multi-
variate analysis, it was determined that performance status and 
type of treatment were independent factors influencing OS. 
The risk of death in patients with WHO/ECOG grade 2 increased 
by three times (PS 0–1 vs. 2, HR: 3.0; 95% CI: 1.4–6.6; p = 0.006). 
Increased risk of death was observed in patients treated with 
radiotherapy alone (HR: 2.4; 95% CI: 1.0–5.6; p = 0.04) compared 
with concurrent radiochemotherapy (tab. III). 
Discussion
The optimal management of NSCLC patients depends on 
multiple factors, including the clinical stage of the disease, the 
potential to achieve a complete resection, the patient’s overall 
condition, comorbidities and preferences. The main option for 
CS I–IIIA (N0–1) NSCLC remains surgery, for clinical stages: IIIA 
(N2), IIIB, and unresectable I–IIIA (N0–1) the standard of care 
is radiochemotherapy [10].
The current analysis concerned patients qualified for treat-
ment before and after the Polish National Program of Diagnosis 
and Treatment of Oncological Diseases was set. Before 2015, in 
our centre, the decision to use the appropriate treatment was 
made by a team of radiation oncologists, after disqualification 
from surgery by thoracic surgeons. In 2015, we started to 
present patients at a multidisciplinary board with a radiation 
oncologist, a medical oncologist, a radiologist and a thoracic 
surgeon, where an accurate treatment plan was chosen. 
Curative radiotherapy alone was chosen for elders and 
patients with a poorer performance status, who had con-
Table III. Uni- and multivariate survival analysis by Cox regression model
    Univariate analysis   Multivariate analysis  
Variables   HR (95% CI) p HR (95% CI) p
Age (start of radiotherapy)
  ≤64 years 1.0 reference   1.0 reference  
  >64 years 1.4 (0.9–2.2) 0.17 0.79 (0.4–1.6) 0.50
Sex      
  women 1.0 reference  
 
  men 1.3 (0.7–2.3) 0.43
BMI      
  ≤26 1.0 reference  
 
  >26 0.9 (0.6–1.5) 0.76
Place of residence      
  village 1.0 reference  
   cities ≤100 thous 1.2 (0.7–2.0) 0.59
  cities >100 thous 1.1 (0.6–2.2) 0.97
Distance from place of residence to Nu-Med Center
  >67 km 1.0 reference    
  ≤67 km 1.3 (0.8–2.1) 0.30  
Performance status according to WHO/ECOG scale during first visit
  0–1 1.0 reference   1.0 reference  
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Figure 3. Overall survival by performance status during the first visit
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traindications to chemotherapy or in whom the application 
of the combined treatment would significantly increase its 
toxicity. The 2-year overall survival of our patients treated with 
radiotherapy only was 25% and this was at the upper limit of 
the survival time reported in the literature: 5–28% [11–15]. 
Patients in good general condition without significant 
comorbidities were qualified for combined therapies. At mul-
tidisciplinary meetings, concurrent radiochemotherapy was 
the preferred option. Sequential treatment was selected when 
the baseline tumour volume excluded radical radiotherapy and 
chemotherapy would provide a chance to reduce tumour mass 
(more advanced clinical stage, positive lymph node status).
The addition of chemotherapy to radiation has been the 
subject of many trials and several meta-analyses. Firstly, its 
beneficial influence on survival was demonstrated in the case 
of sequential radiochemotherapy in comparison with radical 
    Univariate analysis   Multivariate analysis  
Clinical stage      
  IB 1.0 reference    
  IIA 1.3 (0.2–7.9) 0.77
  IIB 2.1 (0.4–10.4) 0.38
  IIIA–B 0.8 (0.3–2.7) 0.76
Lymph nodes 
status      
  N– 1.0 reference    
  N+ 1.1 (0.6–2.2) 0.78  
Tumor localization      
  left 1.0 reference    
  right 1.2 (0.7–2.0) 0.51*  
Type of histopathology
  adenocarcinoma 1.0 reference    
  planoepitheliale 1.4 (0.7–2.4) 0.32^  
PET      
  yes 1.0 reference  
 
  no 1.2 (0.7–1.9) 0.51
Time of treatment from radiochemotherapy to end of radiotherapy 
  >47.5 days 1.0 reference    
  ≤47.5 days 1.2 (0.7–1.8) 0.55  
Type of treatment      
  concurrent radiochemotherapy   1.0 reference  
  alone radiotherapy 2.1 (1.1–4.1) 0.02 2.4 (1.0–5.6) 0.04
  sequential radiochemotherapy 1.2 (0.7–2.3) 0.53 1.1 (0.6–2.1) 0.72
* patients with mediastinum tumor localization were excluded from the analysis
^ patients with undetermined type of histopathology were excluded from the analysis
radiation alone. Adding induction chemotherapy to radio-
therapy increased overall survival to 26–31% at two years [14, 
16–18]. Secondly, the introduction of concurrent radiochemo-
therapy: although this intensification of treatment is associated 
with higher toxicity, most trials showed better survival with 
a concurrent association in comparison with sequential the-
rapy [17, 19–24]. Combining chemotherapy and radiotherapy 
simultaneously increases 2-year overall survival to 35.6–55.6% 
[8, 17, 18, 23]. 
Our study showed the significant advantage of radioche-
motherapy in survival outcomes when compared with radio-
therapy alone. The 2-year survival of NSCLC patients treated 
with sequential and concomitant radiochemotherapy was 
37% and 46% respectively. The results were comparable to 
those published in clinical trials and meta-analyses. However, 
this raport did not manage to show a significant difference in 
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efficiency between sequential and concomitant therapy. This 
could be limited by the small size of the subgroups compared. 
Unfortunately, our center, especially in the first years of ope-
ration, had no impact on the choice of combination therapy 
(simultaneous vs. sequential). The majority of patients who 
were suitable for concurrent treatment were referred to our 
department with no initial PET-CT scan and after the admini-
stration of induction chemotherapy – without the decision of 
a multidisciplinary board.
In the multivariate analysis, the type of treatment and 
performance status were independent factors influencing 
OS. We estimated the statistically significant increasing risk of 
death in patients treated with radiotherapy alone in compari-
son with concurrent radiochemotherapy and in patients with 
WHO/ECOG grade 2 at the first consultation. Polish colleagu-
es also confirmed that performance status had a significant 
association with overall survival [25]. In our analyses, four PS 
2 patients were treated with sequential chemoradiotherapy, 
and their ECOG status was probably an effect of the extent of 
the disease and chemotherapy toxicity. 
In Poland, apart from clinical trias, institutional reports on 
the effectiveness of oncologic treatment of lung cancer are 
still lacking. A similar type of institutional report with a survival 
analysis of NSCLC patients was noted in the case of patients 
treated in the Warmia and Mazuria Oncology Center in Olsztyn, 
Poland. The authors showed treatment results for 130 patients 
treated with chemoradiotherapy in CS IIIA–IIIB and the 2-year 
overall survival was 37% [25]. The results are consistent with 
those reported by our analysis. 
Nonetheless, we are aware of the limitations of this study. It 
is a retrospective analysis, with a small sample and a short ob-
servation time. Comparison of the groups also has limited value 
because of the small subgroups and potential selection bias.
Conclusions
The survival data of NSCLC patients treated in the Nu-Med 
Radiotherapy Center in Elblag is comparable to those publi-
shed in other papers. Forty-six percent of patients treated with 
concurrent radiochemotherapy survived 2 years. The main risk 
factors which decreased OS were: the type of therapy and per-
formance status. A significantly worse prognosis was noted in 
the case of radiation alone compared to radiochemotherapy. 
and poorer performance status during first consultation. Parti-
cular attention should be paid to the proper qualification of the 
lung cancer patient for the appropriate treatment – preferebly 
during multidisciplinary meetings. 
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